SPA
PCRX icon

Sherbrooke Park Advisers’s Pacira BioSciences PCRX Stock Holding History

Sherbrooke Park Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-29,342
Closed -$442K – 1065
2024
Q3 		$442K Buy
29,342
+13,005
+80% +$222K 0.1% 360
2024
Q2 		$467K Buy
+16,337
New +$465K 0.08% 444
2023
Q4 		– Sell
-8,951
Closed -$275K – 625
2023
Q3 		$275K Buy
+8,951
New +$323K 0.09% 344

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sherbrooke Park Advisers's PCRX Position: Q4 2024 in Review

Sherbrooke Park Advisers sold out of Pacira BioSciences (PCRX) in Q4 2024, closing a stake of 29,342 shares — an estimated $442K sold.

Sherbrooke Park Advisers first reported a position in PCRX in Q3 2023 and held it in 3 quarters. The position peaked at $467K in Q2 2024. 233 funds tracked by Wall St. Rank hold PCRX as of Q4 2024.

  • Sherbrooke Park Advisers reported no remaining Pacira BioSciences position as of Q4 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 29,342 Pacira BioSciences shares in Q4 2024, an estimated $442K.
  • Sherbrooke Park Advisers first reported a position in Pacira BioSciences in Q3 2023 and held it in 3 quarters.
  • Sherbrooke Park Advisers's Pacira BioSciences position peaked at $467K in Q2 2024.
  • 233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.